Valsartan

Valsartan
Clinical data
Trade names Diovan
AHFS/Drugs.com Monograph
MedlinePlus a697015
License data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration		 oral
ATC code C09CA03 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 25%
Protein binding 95%
Biological half-life 6 hours
Excretion Renal 30%, biliary 70%
Identifiers
CAS Number 137862-53-4 YesY
PubChem (CID) 60846
IUPHAR/BPS 3937
tritiated: 593
DrugBank DB00177 YesY
ChemSpider 54833 YesY
UNII 80M03YXJ7I YesY
KEGG D00400 YesY
ChEBI CHEBI:9927 YesY
ChEMBL CHEMBL1069 YesY
ECHA InfoCard 100.113.097
Chemical and physical data
Formula C24H29N5O3
Molar mass 435.519 g/mol
3D model (Jmol) Interactive image
  (verify)

Valsartan (trade name Diovan) is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor. Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack.

Medical uses

Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.[1][2]

There is contradictory evidence with regard to treating people with heart failure with a combination of an angiotensin receptor blocker like valsartan and an angiotensin-converting enzyme inhibitor, with two major clinical trials (CHARM-additive and ValHeFt) showing a reduction in death, and two others (VALIANT and ONTARGET) showing no benefits, and more adverse effects including heart attacks.[1]

In people with type II diabetes and high blood pressure or albumin in the urine, valsartan is used to slow the worsening and the development end-stage renal disease.[3]

Contraindications

The packaging for valsartan includes a warning stating the drug should not be used with the renin inhibitor aliskiren in people with diabetes mellitus. It also states the drug should not be used in people with kidney disease.[2]

Valsartan falls in FDA pregnancy category D and includes a black box warning for fetal toxicity.[2] Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be started.[2] The US labeling makes no recommendation regarding continuation or discontinuation of valsartan for breast-feeding mothers.[2] The Canadian labeling does not recommend use by nursing women.[4]

Side effects

Rates of side effects depends on the reason the medication is used.

Heart failure

Rates of adverse effects are based on a comparison versus placebo in people with heart failure.[5] Most common side effects include dizziness (17% vs 9% ), low blood pressure (7% vs 2%), and diarrhea (5% vs 4%).[5] Less common side effects include joint pain, fatigue, and back pain (all 3% vs 2%).[5]

Hypertension

Clinical trials for valsartan treatment for hypertension versus placebo demonstrate side effects like viral infection (3% vs 2%), fatigue (2% vs 1%) and abdominal pain (2% vs 1%). Minor side effects that occurred at >1% but were similar to rates from the placebo group include:[5]

Interactions

Co-Diovan (Valsartan and hydrochlorothiazide)

The US prescribing information lists the following drug interactions for valsartan:

Mechanism of action

Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure.[6] The drug binds to angiotensin type I receptors (AT1), working as an antagonist. This mechanism of action is different than the ACE inhibitor drugs, which block the conversion of angiotensin I to angiotensin II. Since valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by other enzymes as well as ACE. Also, valsartan does not affect the metabolism of bradykinin like ACE inhibitors do.[6]

Economics

In 2010, valsartan (trade name Diovan) achieved annual sales of $2.052 billion in the United States and $6.053 billion worldwide.[7] The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012.[8][9]

Research

In people with impaired glucose tolerance, valsartan may decrease the incidence of developing diabetes mellitus type 2. However, the absolute risk reduction is small (less than 1 percent per year) and diet, exercise or other drugs, may be more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown.[10]

In one study of people without diabetes, valsartan reduced the risk of developing diabetes mellitus over amlodipine, mainly for those with hypertensive.[11]

A prospective study demonstrated a reduction in the incidence and progression of Alzheimer's disease and dementia.[12]

Combination drugs

Amlodipine and valsartan is a combination drugs for hypertention. The combination is not approved for use by anyone younger than 18 years old. For who have diabetes or kidney disease the combination drugs cannot be given with medication that contains aliskiren.[13]

See also

References

  1. 1 2 Randa, Hilal-Dandan (2011). "Chapter 26. Renin and Angiotensin". In Brunton, L. L.; Chabner, Bruce; Knollmann, Björn C. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8.
  2. 1 2 3 4 5 6 "Diovan prescribing information" (PDF). Novartis.
  3. ↑ Inzucchi, Silvio E.; Bergenstal, Richard M.; Buse, John B.; Diamant, Michaela; Ferrannini, Ele; Nauck, Michael; Peters, Anne L.; Tsapas, Apostolos; Wender, Richard (2015-01-01). "Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes". Diabetes Care. 38 (1): 140–149. doi:10.2337/dc14-2441. ISSN 0149-5992. PMID 25538310.
  4. ↑ "DIOVAN Product Monograph". Health Canada Drug Product Database. Novartis Pharmaceuticals Canada Inc. Retrieved 5 November 2015.
  5. 1 2 3 4 "DailyMed - VALSARTAN - valsartan tablet". dailymed.nlm.nih.gov. Retrieved 2015-11-04.
  6. 1 2 Katzung, Bertram G; Trevor, Anthony J. (2015). "Chapter 11". Basic & Clinical Pharmacology (13 ed.). McGraw-Hill Education. ISBN 978-0071825054.
  7. ↑ "Novartis Annual Report 2010" (PDF).
  8. ↑ Philip Moeller (April 29, 2011). "Blockbuster Drugs That Will Go Generic Soon". U.S.News & World Report.
  9. ↑ Eva Von Schaper (August 5, 2011). "Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires". Bloomberg.
  10. ↑ McMurray JJ, Holman RR, Haffner SM, et al. (April 2010). "Effect of valsartan on the incidence of diabetes and cardiovascular events" (PDF). The New England Journal of Medicine. 362 (16): 1477–90. doi:10.1056/NEJMoa1001121. PMID 20228403.
  11. ↑ Kjeldsen SE1, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A. "Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.". Retrieved September 27, 2016.
  12. ↑ Li NC, Lee A, Whitmer RA, et al. (January 2010). "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis" (PDF). BMJ. 340: b5465. doi:10.1136/bmj.b5465. PMC 2806632Freely accessible. PMID 20068258.
  13. ↑ "amlodipine and valsartan". Retrieved September 2, 2016.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.